Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
30 juil. 2024 07h00 HE
|
Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
24 juin 2024 16h37 HE
|
Arvinas Inc.
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage...
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
21 juin 2024 07h00 HE
|
Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the...
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
17 juin 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...
Arvinas to Participate in Upcoming Investor Conferences
03 juin 2024 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
23 mai 2024 17h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
16 mai 2024 06h00 HE
|
Arvinas Inc.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
09 mai 2024 16h42 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
07 mai 2024 07h00 HE
|
Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
Arvinas to Present at Upcoming Investor Conferences
02 mai 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...